ID22975A - METHODS AND COMPOSITIONS TO MODULATE RESPONSE TO Corticosteroids - Google Patents

METHODS AND COMPOSITIONS TO MODULATE RESPONSE TO Corticosteroids

Info

Publication number
ID22975A
ID22975A IDW991185A ID991185A ID22975A ID 22975 A ID22975 A ID 22975A ID W991185 A IDW991185 A ID W991185A ID 991185 A ID991185 A ID 991185A ID 22975 A ID22975 A ID 22975A
Authority
ID
Indonesia
Prior art keywords
corticosteroids
compositions
methods
modulate response
modulate
Prior art date
Application number
IDW991185A
Other languages
Indonesian (id)
Inventor
Les Sekut
Adam Carter
Tariq Ghayur
Subhashis Banerjee
Daniel E Tracey
Original Assignee
Basf Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/820,692 external-priority patent/US6054487A/en
Application filed by Basf Ag filed Critical Basf Ag
Publication of ID22975A publication Critical patent/ID22975A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
IDW991185A 1997-03-18 1998-03-12 METHODS AND COMPOSITIONS TO MODULATE RESPONSE TO Corticosteroids ID22975A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/820,692 US6054487A (en) 1997-03-18 1997-03-18 Methods and compositions for modulating responsiveness to corticosteroids
US1634698A 1998-01-30 1998-01-30

Publications (1)

Publication Number Publication Date
ID22975A true ID22975A (en) 1999-12-23

Family

ID=26688484

Family Applications (1)

Application Number Title Priority Date Filing Date
IDW991185A ID22975A (en) 1997-03-18 1998-03-12 METHODS AND COMPOSITIONS TO MODULATE RESPONSE TO Corticosteroids

Country Status (20)

Country Link
EP (1) EP0998300A1 (en)
JP (1) JP2002504091A (en)
KR (1) KR20000076420A (en)
CN (1) CN1269722A (en)
AU (1) AU734756B2 (en)
BG (1) BG103808A (en)
BR (1) BR9810409A (en)
CA (1) CA2282845A1 (en)
DE (1) DE998300T1 (en)
ES (1) ES2146192T1 (en)
HU (1) HUP0104439A3 (en)
ID (1) ID22975A (en)
IL (1) IL131815A0 (en)
NO (1) NO994506L (en)
NZ (1) NZ337769A (en)
PL (1) PL336464A1 (en)
SI (1) SI20110A (en)
SK (1) SK122199A3 (en)
TR (1) TR199902615T2 (en)
WO (1) WO1998041232A2 (en)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
ZA95960B (en) * 1994-03-14 1995-10-10 Genetics Inst Use of interleukin-12 antagonists in the treatment of autoimmune diseases
US6706264B1 (en) 1994-03-14 2004-03-16 Genetics Institute, Llc Use of IL-12 antagonists in the treatment of conditions promoted by an increase in levels of IFN-y
US7220717B2 (en) 1997-08-14 2007-05-22 Yeda Research And Development Company Ltd. Interleukin-18 binding proteins, their preparation and use
US7704944B2 (en) 1997-08-14 2010-04-27 Yeda Research And Development Company Ltd. Interleukin-18 binding proteins, their preparation and use for the treatment of sepsis
IL121860A0 (en) 1997-08-14 1998-02-22 Yeda Res & Dev Interleukin-18 binding proteins their preparation and use
US6184210B1 (en) 1997-10-10 2001-02-06 Cytovia, Inc. Dipeptide apoptosis inhibitors and the use thereof
AR015966A1 (en) * 1997-10-17 2001-05-30 Smithkline Beecham Corp USE OF A PDE4 INHIBITOR COMPOUND FOR THE PREPARATION OF A USEFUL MEDICINAL PRODUCT FOR PRURITE TREATMENT
EP1516630A3 (en) * 1997-10-31 2006-05-03 Wyeth Use of anti-il-12 antibodies in transplantation rejection
ATE274920T1 (en) * 1997-10-31 2004-09-15 Wyeth Corp USE OF ANTI-IL-12 ANTIBODIES IN TRANSPLANT REJECTION
WO1999025737A1 (en) * 1997-11-19 1999-05-27 Tanox Pharma B.V. Compositions and methods for treatment of autoimmune diseases, using a monoclonal antibody to the interleukin-12 beta2-chain
CA2323439A1 (en) * 1998-03-16 1999-09-23 Cytovia, Inc. Dipeptide caspase inhibitors and the use thereof
EP1140206A4 (en) * 1998-11-27 2002-04-10 Technion Res & Dev Foundation Interferon gamma inducing factor based vaccine and use of same for protective immunity against multiple sclerosis
ES2251248T3 (en) * 1998-12-09 2006-04-16 Protein Design Labs, Inc. USE OF ANTIBODIES AGAINST IL-12 TO TREAT PSORIASIS.
JP2002539183A (en) 1999-03-16 2002-11-19 サイトビア インコーポレイテッド Substituted 2-aminobenzamide caspase inhibitors and uses thereof
US6914128B1 (en) 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
US7883704B2 (en) 1999-03-25 2011-02-08 Abbott Gmbh & Co. Kg Methods for inhibiting the activity of the P40 subunit of human IL-12
DE19915465A1 (en) * 1999-04-06 2000-10-19 Apotech Res & Dev Ltd Use of a caspase inhibitor to inhibit cell proliferation and use of one or more caspase inhibitors to treat diseases based on lymphocyte hyperproliferation or to suppress an immune response by lymphocytes
BR0009610A (en) 1999-04-09 2002-02-13 Cytovia Inc Caspase inhibitors and their use
IL131047A0 (en) * 1999-07-22 2001-01-28 Yeda Res & Dev Use of il-18 inhibitors
AU775291B2 (en) 1999-08-27 2004-07-29 Cytovia, Inc. Substituted alpha-hydroxy acid caspase inhibitors and the use thereof
WO2001019373A2 (en) * 1999-09-17 2001-03-22 Basf Aktiengesellschaft Methods and compositions for modulating responsiveness to corticosteroids
US6566338B1 (en) 1999-10-12 2003-05-20 Cytovia, Inc. Caspase inhibitors for the treatment and prevention of chemotherapy and radiation therapy induced cell death
SK12942002A3 (en) 2000-02-10 2003-05-02 Abbott Laboratories Antibodies that bind human interleukin-18 and methods of making and using
DE60121440T2 (en) * 2000-06-06 2007-06-28 Glaxo Group Ltd., Greenford A cancer treatment composition containing an antineoplastic agent and a PDE4 inhibitor
AU7250301A (en) * 2000-06-22 2002-01-02 Willy Ben Moussa Ben Mohammed Use of glucocorticosteroids for producing a medicament to treat oligotrichia
US20020025317A1 (en) * 2000-07-20 2002-02-28 Schering Ag Bispecific monoclonal antibodies to IL-12 and IL-18
WO2002022127A1 (en) * 2000-09-13 2002-03-21 Isis Innovation Limited Use of phosphodiesterase inhibitors for the treatment of anorectal disorders
EP1199074A1 (en) * 2000-09-15 2002-04-24 Warner-Lambert Company Pharmaceutical composition for preventing or treating a disease associated with an excess of il-12 production
EP1188438A1 (en) * 2000-09-15 2002-03-20 Warner-Lambert Company Pharmaceutical composition for preventing or treating a disease associated with an excess of Il-12 production
WO2002060479A1 (en) * 2001-01-29 2002-08-08 Applied Research Systems Ars Holding N.V. Use of il-18 inhibitors for the treatment and/or prevention of heart disease
WO2002092008A2 (en) * 2001-05-16 2002-11-21 Yeda Research And Development Co., Ltd. Use of il-18 inhibitors for the treatement or prevention of sepsis
TR201809008T4 (en) 2001-06-26 2018-07-23 Amgen Fremont Inc Antibodies against opgl.
IL161267A0 (en) * 2001-10-05 2004-09-27 Combinatorx Inc Combinations for the treatment of immunoinflammatory disorders
JP2003342196A (en) * 2002-05-31 2003-12-03 Mukku:Kk Composition for intravenous injection, method of production for the same and its preparation
MXPA05003152A (en) * 2002-09-24 2006-04-27 Combinatorx Inc Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines.
WO2004028545A1 (en) * 2002-09-25 2004-04-08 Astrazeneca Ab A COMBINATION OF A LONG-ACTING β2-AGONIST AND A GLUCOCORTICOSTEROID IN THE TREATMENT OF FIBROTIC DISEASES
WO2004067006A1 (en) * 2003-01-27 2004-08-12 Pharmacia Corporation Combination of a pde iv inhibitor and a tnf-alpha antagonist
US20050100965A1 (en) 2003-11-12 2005-05-12 Tariq Ghayur IL-18 binding proteins
WO2005110450A1 (en) * 2004-05-17 2005-11-24 Keio University Medicinal composition and therapeutic method
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
DK1808446T3 (en) * 2004-07-16 2012-05-14 Atsuo Sekiyama IL-18 receptor antagonist and pharmaceutical composition containing the antagonist
US20070287689A1 (en) * 2004-10-13 2007-12-13 Kyowa Hakko Kogyo Co., Ltd. Therapeutic And/Or Preventive Agents For Chronic Skin Diseases
CN106075449A (en) 2005-07-14 2016-11-09 尼奥塞蒂克斯公司 Enhanced lipolytic formulation for the sustained release of regional adipose tissue treatment
ES2398480T3 (en) * 2006-10-17 2013-03-19 Lithera, Inc. Procedures, compositions, and formulations for the treatment of thyroid eye disease
AU2008205512B2 (en) 2007-01-16 2014-06-12 Abbvie Inc. Methods for treating psoriasis
EP2142565A4 (en) 2007-03-29 2010-03-31 Abbott Lab Crystalline anti-human il-12 antibodies
EP2274333A4 (en) 2008-03-18 2011-06-15 Abbott Lab Methods for treating psoriasis
US9132084B2 (en) 2009-05-27 2015-09-15 Neothetics, Inc. Methods for administration and formulations for the treatment of regional adipose tissue
SG190878A1 (en) 2010-11-24 2013-07-31 Lithera Inc Selective, lipophilic, and long-acting beta agonist monotherapeutic formulations and methods for the cosmetic treatment of adiposity and contour bulging
WO2015063669A1 (en) 2013-10-30 2015-05-07 Wockhardt Limited Pharmaceutical compositions comprising combination of roflumilast and acebrophylline or pharmaceutically acceptable salts thereof
WO2023049809A1 (en) * 2021-09-22 2023-03-30 Iolyx Therapeutics, Inc. Methods of treating ocular inflammatory diseases

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3320125A (en) * 1964-04-28 1967-05-16 Merck & Co Inc Inhalation aerosol composition
NZ235222A (en) * 1989-09-08 1992-11-25 Glaxo Group Ltd Inhalatory composition comprising salmeterol and beclomethasone dipropionate
IL104068A (en) * 1991-12-12 1998-10-30 Glaxo Group Ltd Surfactant-free pharmaceutical aerosol formulation comprising 1,1,1,2-tetrafluoroethane or 1,1,1,2,3,3,3-heptafluoro-n- propane as propellant
GB9202519D0 (en) * 1992-02-06 1992-03-25 Glaxo Group Ltd Medicaments
MX9304585A (en) * 1992-07-31 1994-03-31 Glaxo Group Ltd PHARMACEUTICAL FORMULATION IN AEROSOL, CAN SUITABLE TO RELEASE THE FORMULATION AND INHALER OF DOSE DOSE THAT COMPRISES THE CAN.
GB9426252D0 (en) * 1994-12-24 1995-02-22 Glaxo Group Ltd Pharmaceutical composition
JP3573213B2 (en) * 1995-04-14 2004-10-06 グラクソ、ウェルカム、インコーポレーテッド Metered dose inhaler for beclomethasone dipropionate

Also Published As

Publication number Publication date
IL131815A0 (en) 2001-03-19
SK122199A3 (en) 2000-12-11
TR199902615T2 (en) 2000-03-21
WO1998041232A3 (en) 2000-10-05
NO994506D0 (en) 1999-09-17
PL336464A1 (en) 2000-06-19
CN1269722A (en) 2000-10-11
AU734756B2 (en) 2001-06-21
JP2002504091A (en) 2002-02-05
CA2282845A1 (en) 1998-09-24
KR20000076420A (en) 2000-12-26
NZ337769A (en) 2002-09-27
ES2146192T1 (en) 2000-08-01
AU6760498A (en) 1998-10-12
WO1998041232A2 (en) 1998-09-24
BG103808A (en) 2000-07-31
HUP0104439A3 (en) 2002-08-28
DE998300T1 (en) 2001-03-01
NO994506L (en) 1999-11-17
EP0998300A1 (en) 2000-05-10
BR9810409A (en) 2000-08-22
SI20110A (en) 2000-06-30
HUP0104439A2 (en) 2002-04-29

Similar Documents

Publication Publication Date Title
ID22975A (en) METHODS AND COMPOSITIONS TO MODULATE RESPONSE TO Corticosteroids
ID24284A (en) ABSORBEN PRODUCTS AND EQUIPMENT AND METHODS TO PRODUCE SUCH ABSORBEN PRODUCTS
ID17437A (en) METHODS AND COMPOSITIONS TO MAKE LIGHT SKIN
ID19588A (en) ESTER AND HETEROSICLIC AMIDA
ID19422A (en) PYRIDINA AND SUBSTITUTED BIFENYL
ID20400A (en) COMPOSITION AND METHODS FOR INHIBITING AGING DUE TO LIGHT ON SKIN
ID24524A (en) COMBINATIONS FOR REDUCTION OF ALDOSA REDUCTIVES AND GLICOGEN PHOSPHEREILASE OBSTACLES
FI972496A (en) Fusarium isolate and lipases, cutinases and enzyme compositions derived therefrom
ID24476A (en) ARILSULFONAMIDA AND ITS ANALOGUE
ID23953A (en) 5-ALKIL-2-ARILAMINOFENILASETAT ACID AND ITS DECLARATION
ID22807A (en) RESULTS OF 1-ARIL AND PYRIDYLPIRAZOL RESULTS FOR PESTICIDES
FI962932A (en) Modulators of anchor protein function
ID17233A (en) METHODS AND [EQUIPMENT TO CONTROL TANK EXTENSION TANK AND TEMPERATURE TANK
FR2772599B1 (en) COSMETIC COMPOSITION AND USES THEREOF
ID24828A (en) PHARMACY COMPOSITIONS OF TIZOKSIANIDA AND NITAZOKSANIDA
ID18456A (en) PRODUCTION-JOINT 6-AMINOCAPRONITRIL AND HEXSAMETYLENADIAMINA
ID16923A (en) BITUMENT COMPOSITIONS AND THE PROCESS OF MAKING
ID30135A (en) COMPOSITIONS AND METHODS TO CONTROL INSECTS
ID20911A (en) CIGARETTE AS WELL AS THE METHOD AND EQUIPMENT TO MAKE CIGARETTE
ID25848A (en) COMPOSITIONS AND METHODS OF SYNERGIC HERBISIDES
FR2772608B1 (en) COSMETIC COMPOSITION AND USES THEREOF
ID18459A (en) PRODUCTION-JOINT 6-AMINOCAPRONITRIL AND HEXSAMETYLENADIAMINA
ID24463A (en) METHOD OF IMPROVING THE AVAILABILITY OF PHYSOFENADIN AND ITS DECLARATION
ID21862A (en) COMPOSITIONS OF INSECTICIDE AND MITISIDE
ID22534A (en) COMPOSITIONS OF INSECTICIDE AND MITISIDE